G Jerusalem

Summary

Country: Belgium

Publications

  1. ncbi Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL
    Guy H M Jerusalem
    Department of Medicine, University of Liege, Liege, Belgium
    Clin Lymphoma 3:56-61. 2002
  2. ncbi [Targeted therapies in breast cancer]
    G Jerusalem
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:379-84. 2011
  3. ncbi [Angiosarcoma in chronic lymphoedema: a case of Stewart-Treves syndrome]
    E Gonne
    Universite de Liege, Belgique
    Rev Med Liege 64:409-13. 2009
  4. ncbi [Hypofractionated postoperative radiotherapy for breast cancer]
    P A Coucke
    Service de Radiotherapie, CHU de Liege, Belgique
    Rev Med Liege 65:10-4. 2010
  5. ncbi [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques]
    N Withofs
    Service de Medecine Nucleaire, CHU de Liege, Belgique
    Rev Med Liege 66:288-90. 2011
  6. ncbi [Positron emission tomography: a revolution in oncology?]
    Guy Jerusalem
    Service d Oncologie Medicale, Universite de Liege, Liege, Belgique
    Rev Prat 53:1629-30. 2003
  7. ncbi Evaluation of therapy for lymphoma
    Guy Jerusalem
    Division of Medical Oncology, Department of Medicine, University of Liege, CHU Sart Tillman B35, B 4000 Liege 1, Belgium
    Semin Nucl Med 35:186-96. 2005
  8. ncbi [The role of multidisciplinary tumor board discussions in treatment decisions]
    G Jerusalem
    Oncologie Médicale, CHU de Liege, Belgique
    Rev Med Liege 66:311-4. 2011
  9. ncbi PET scan imaging in oncology
    G Jerusalem
    Department of Medicine, Division of Medical Oncology and Hematology, CHU Sart Tilman, B35, B 4000 Liege 1, Belgium
    Eur J Cancer 39:1525-34. 2003
  10. ncbi Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
    G Jerusalem
    Department of Medicine, Division of Medical Oncology and Hematology, Liege, Belgium
    Ann Oncol 14:123-30. 2003

Collaborators

Detail Information

Publications48

  1. ncbi Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL
    Guy H M Jerusalem
    Department of Medicine, University of Liege, Liege, Belgium
    Clin Lymphoma 3:56-61. 2002
    ..In the second part, the potential role of PET in the staging and follow-up of low-grade NHL is discussed. Published data indicate that PET may contribute to the management of low-grade follicular NHL...
  2. ncbi [Targeted therapies in breast cancer]
    G Jerusalem
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:379-84. 2011
    ..This article also reviews other targeted treatments of interest in the field of breast cancer including antiangiogenic agents and drugs targeting the PI3K-AKT-mTOR pathway...
  3. ncbi [Angiosarcoma in chronic lymphoedema: a case of Stewart-Treves syndrome]
    E Gonne
    Universite de Liege, Belgique
    Rev Med Liege 64:409-13. 2009
    ..Chemotherapy is only used in more advanced cases, not curable by surgery alone...
  4. ncbi [Hypofractionated postoperative radiotherapy for breast cancer]
    P A Coucke
    Service de Radiotherapie, CHU de Liege, Belgique
    Rev Med Liege 65:10-4. 2010
    ..Based on this evidence a new treatment algorithm has been built up as it has been shown that those schedules do provide similar levels of local control with comparable or an even lower risk of toxicity...
  5. ncbi [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques]
    N Withofs
    Service de Medecine Nucleaire, CHU de Liege, Belgique
    Rev Med Liege 66:288-90. 2011
    ....
  6. ncbi [Positron emission tomography: a revolution in oncology?]
    Guy Jerusalem
    Service d Oncologie Medicale, Universite de Liege, Liege, Belgique
    Rev Prat 53:1629-30. 2003
  7. ncbi Evaluation of therapy for lymphoma
    Guy Jerusalem
    Division of Medical Oncology, Department of Medicine, University of Liege, CHU Sart Tillman B35, B 4000 Liege 1, Belgium
    Semin Nucl Med 35:186-96. 2005
    ..We calculated, from data of 17 studies in end-of-treatment evaluation, a sensitivity of 76%, a specificity of 94%, a PPV of 82%, a NPV 92%, and an accuracy of 89%...
  8. ncbi [The role of multidisciplinary tumor board discussions in treatment decisions]
    G Jerusalem
    Oncologie Médicale, CHU de Liege, Belgique
    Rev Med Liege 66:311-4. 2011
    ..Quality of life is important if only a palliative approach can be offered. The final decision concerning the treatment will be taken by the patient because he/she has the right to refuse the best treatment for personal reasons...
  9. ncbi PET scan imaging in oncology
    G Jerusalem
    Department of Medicine, Division of Medical Oncology and Hematology, CHU Sart Tilman, B35, B 4000 Liege 1, Belgium
    Eur J Cancer 39:1525-34. 2003
    ....
  10. ncbi Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
    G Jerusalem
    Department of Medicine, Division of Medical Oncology and Hematology, Liege, Belgium
    Ann Oncol 14:123-30. 2003
    ..We undertook this study to examine the value of whole-body positron emission tomography (PET) for the detection of preclinical relapse...
  11. ncbi [Positron emission tomography in oncology: an update]
    Guy Jerusalem
    Service d Oncologie Medicale, Department de Medecine, Universite de Liege, Belgique
    Rev Prat 57:1864-70. 2007
    ..Major improvements were also observed with conventional imaging techniques over the past 10 years. It is important to avoid long waiting lists because otherwise treatment delay may counterbalance the benefit of PET studies...
  12. ncbi Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
    G Jerusalem
    Department of Medicine, University of Liege, Belgium
    Ann Oncol 12:825-30. 2001
    ..We undertook this study to determine factors influencing the detection of lesions by PET in low-grade NHL and to evaluate the utility of PET in this indication...
  13. ncbi Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease
    G Jerusalem
    Medical Oncology, CHU Sart Tilman, B35 B 4000, Li ge 1, Belgium
    Haematologica 86:266-73. 2001
    ..In the present study we evaluated the role of (18)F-FDG PET compared to routine procedures for the staging of patients with HD...
  14. ncbi Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
    G Jerusalem
    Department of Medicine, Division of Onco Hematology, University of Liege, Liege, Belgium
    Haematologica 85:613-8. 2000
    ..Therefore, we studied the value of (18)F-FDG PET for early evaluation of response in patients with non-Hodgkin's lymphoma (NHL)...
  15. ncbi Positron emission tomography imaging for lymphoma
    Guy Jerusalem
    Division of Hemato Oncology, Department of Medicine, Medical Oncology CHU, University of Liege, Sart Tilman B35, B 4000 Liege, Belgium
    Curr Opin Oncol 17:441-5. 2005
    ..To review the current role and the limitations of F-fluorodeoxygenase positron emission tomography in the management of lymphoma, with a particular focus on studies published since January 2004...
  16. ncbi Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
    G Jerusalem
    Division of Onco haematology, University Hospital, Liege, Belgium
    Nucl Med Commun 20:13-20. 1999
    ..Compared with conventional techniques, however, it does not appear to offer much improvement for staging but provides a satisfactory base for follow-up...
  17. ncbi Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)
    F Najjar
    Divisions of Nuclear Medicine and Onco-Hematology, University Hospital, Liege, Belgium
    Cancer Biother Radiopharm 16:297-304. 2001
    ..The combination PET/CT/physical examination seems to be more sensitive than the conventional approach for staging low grade NHL. Its sensitivity however is unacceptably low for diagnosing bone marrow infiltration...
  18. ncbi [End of treatment evaluation in patients with aggressive non-Hodgkin's lymphoma]
    V Warland
    Service d Hémato Oncologie, CHU Sart Tilman, Liege
    Rev Med Liege 57:779-84. 2002
    ..18F-fluorodeoxyglucose is not a tumor specific radiotracer...
  19. ncbi [Breast cancer in young women]
    C Andre
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:397-9. 2011
    ..The role of radiotherapy is very important in these patients with high risk of local recurrence. The progress in adjuvant treatment of very young patients requires studies of tailored treatments...
  20. ncbi [Monoclonal antibodies and breast cancer. Current therapeutic progress]
    J Collignon
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 64:279-83. 2009
    ..We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer...
  21. ncbi [Systemic chemotherapy and breast cancer]
    J Collignon
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:372-8. 2011
    ..When we have to decide wether chemotherapy is indicated, we need to well balance the treatment risks and benefits because gain in survival is important but reducing short and long term toxicity is also a challenge...
  22. ncbi [Breast cancer in the elderly patient]
    M Martin
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:400-8. 2011
    ....
  23. ncbi [Management and follow-up of a consecutive series of 411 surgically treated breast cancer patients]
    E Lifrange
    Service de Sénologie, CHU de Liege, Belgique
    Rev Med Liege 66:329-35. 2011
    ..Amongst the 16% of deaths (67/411 Pts), 54% are due to breast cancer progression. The results are discussed with the aim to upgrade the diagnostic and the therapeutic protocols offered to our patients...
  24. ncbi [Hormone therapy for breast cancer]
    E Lifrange
    Service de Sénologie, CHU de Liege, Belgique
    Rev Med Liege 66:367-71. 2011
    ..Efficacy of these medications is dependent on patient's compliance. This article proposes a synthesis of the main knowledges available in the field of breast cancer endocrine therapy...
  25. ncbi The value of positron emission tomography (PET) imaging in disease staging and therapy assessment
    G Jerusalem
    Department of Medicine, Division of Medical Oncology and Hematology, University of Liege, Belgium
    Ann Oncol 13:227-34. 2002
  26. ncbi [Breast cancer and brain metastases]
    A Rorive
    Oncologie Médicale, CHU de Liege, Belgique
    Rev Med Liege 66:299-305. 2011
    ..Indeed, chemotherapy agents available for the treatment of breast cancer do not cross the hematoencephalic barrier and are thus ineffective. However, some encouraging results have been recently reported with the therapies targeting HER2...
  27. ncbi [Radiotherapy in breast cancer: current standards of treatment, prediction of local recurrence and open questions]
    P Coucke
    Service de Radiotherapie, CHU de Liege, Belgique
    Rev Med Liege 66:320-5. 2011
    ..Predicting the individual local recurrence risk is the search for the "Holy Grail". Methods such as nomograms and genomic profiling are currently tested but need to be validated before their widespread clinical application...
  28. ncbi [Radiation recall dermatitis after oral cyclophosphamide]
    C Mievis
    Service de Radiotherapie, CHU de Liege, Belgique
    Rev Med Liege 64:179-81. 2009
    ..Spontaneous resolution was observed within 6 weeks after discontinuation of cyclophosphamide and with local supportive care. To our knowledge this is the first reported case of radiation recall dermatitis after oral cyclophosphamide...
  29. ncbi [Targeted therapies in breast cancer: current status and perspectives]
    G Jerusalem
    CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 62:2-5. 2007
    ..Another benefit for the patient is the easy access to last generation medical treatments, generally not accessible in our health care system in Belgium outside of clinical trials...
  30. ncbi [Current therapeutic progress in oncology: the development of targeted therapies]
    C Gennigens
    Service d Oncologie Medicale, CHU Sart Tilman, Liege
    Rev Med Liege 62:391-8. 2007
    ..New imaging techniques are under development in order to assess the molecular response to these new approaches...
  31. ncbi [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas]
    C Gennigens
    Charge de cours, Service d Oncologie Medicale, CHU de Liege
    Rev Med Liege 67:437-42. 2012
    ..In this paper, we will review the mechanism of action and the clinical results of pazopanib in renal cell carcinoma and sarcoma...
  32. ncbi [Therapeutic monoclonal antibodies in hemato-oncology]
    C Gennigens
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 64:264-7. 2009
    ..Several mAbs are currently licensed for the treatment of hematological or solid malignancies and many others are expected in the near future...
  33. ncbi Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations
    G Jerusalem
    CHU Sart Tilman, Department of Medicine, Medical Oncology, Liege, Belgium
    Ann Oncol 17:x168-76. 2006
  34. ncbi [Adherence to long-term medication: the particular case of the adjuvant endocrine therapy for breast cancer]
    V Bleret
    Service de Sénologie, CHU de Liege, Belgique
    Rev Med Liege 65:405-8. 2010
    ..With this in mind, we undertook a review of the recent literature on the topic (Pub Med 2003-2009)...
  35. ncbi [Peritoneal carcinomatosis of unknown origin]
    N Marchal
    Universite de Liege, Belgique
    Rev Med Liege 67:582-6. 2012
    ..When this condition affects a woman, it becomes a particular entity with a better outcome, for which a specific first-line treatment should be initiated...
  36. ncbi [Molecular and genetic aspects of triple negative breast cancer and therapeutic implications]
    J Collignon
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:393-6. 2011
    ..This article reviews some recent data in this field and the research on different pathways for the development of new therapies...
  37. ncbi [Primary and secondary prevention of colorectal cancer]
    M Polus
    Service d Oncologie Medicale, CHU Liege
    Rev Med Liege 58:247-53. 2003
    ..Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality...
  38. ncbi [Will targeted therapies replace chemotherapy?]
    J Collignon
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 67:29-36. 2012
    ..The selection of patients who will most benefit from these combinations is still a challenge. Currently, chemotherapy in association with anti-HER2 therapy remains the most effective treatment option...
  39. ncbi [Late relapse of breast cancer after adjuvant chemotherapy]
    L Lousberg
    Universite de Liege, Belgique
    Rev Med Liege 66:306-10. 2011
    ..New hypotheses concerning disseminated tumoral cells and circulating cells will be reported. We will also review data about stem cells, tumor initiating cells and dormancy state...
  40. ncbi Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial
    C Focan
    CHC Clinique Saint Joseph, Liege, Belgium
    Anticancer Res 25:1211-7. 2005
    ..The recommended sequence of both drugs in combination therapy, mainly to avoid neutropenia, is epirubicin day 1 followed by paclitaxel on day 2. Cardiac toxicity remains problematic in either sequence of administration...
  41. ncbi [Circulating tumor cells: detection, characterization and clinical impact]
    C Gilles
    Laboratoire de Biologie des Tumeurs et du Developpement, GIGA Cancer, Universite de Liege, CHU de Liege, Belgique
    Rev Med Liege 66:279-84. 2011
    ..Moreover, enhancing our basic understanding of the metastatic process, CTCs, and DTCs in particular, are thought to contain subpopulations of cells with stem cells properties that would be responsible for relapses...
  42. ncbi [Ductal carcinoma in situ (DCIS): can radiotherapy be avoided?]
    P A Coucke
    Service de radiothérapie et oncologie, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 63:75-81. 2008
    ..Therefore, we think that there is no available evidence to avoid radiotherapy after BCS for DCIS. However, radiotherapy is not indicated after mastectomy...
  43. ncbi [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma]
    C Gennigens
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 65:212-6. 2010
    ..Everolimus (Afinitor), a mTOR ("mammalian Target Of Rapamycin") inhibitor, has just been validated and reimbursed in this setting. In this paper, we will review the mechanism of action and the clinical results of everolimus...
  44. ncbi [Image of the month. Merkel cell tumor: response to chemotherapy]
    M Polus
    Universite de Liege, Service d Oncologie Medicale
    Rev Med Liege 59:67-8. 2004
  45. ncbi European inter-institutional impact study of MammaPrint
    P G Cusumano
    CHU Sart Tilman, Liege, Belgium Electronic address
    Breast 23:423-8. 2014
    ..To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort...
  46. ncbi [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer]
    C Gennigens
    Service d Oncologie Medicale, CHU de Liege, Belgique
    Rev Med Liege 66:452-5. 2011
    ..Trabectedin has just been also validated and reimbursed in patients with ovarian cancer, in partially sensitive recurrence. In this paper, we will review the mechanism of action and the clinical results of trabectedin...
  47. ncbi Does positron emission tomogrpahy have a role in routine clinical practice in patients with Hodgkin's disease?
    Guy H M Jerusalem
    Department of Medicine, Division of Oncology Hematology, University of Liege, Liege, Belgium
    Clin Lymphoma 3:125-6. 2002
  48. ncbi Commentary on "Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?"
    Guy H M Jerusalem
    Department of Medicine, Division of Onco Hematology, University of Liege, Belgium
    Clin Lymphoma 2:249. 2002